inc headquart danver
lead provid medic devic design use
primarili use either cardiac catheter
lab cath lab intervent cardiologist
heart surgeri suit cardiovascular surgeon
patient receiv devic need
prophylact hemodynam support high-risk
angioplasti procedur experienc pre-shock
shock profound cardiogen shock
reason report
estim chang analysi sales/earn
reiter o/v invest rate price target
share follow compani report fiscal
oper result effect in-lin consensu revenu estim
consensu earn growth intern busi
continu deliv top-tier organ revenu growth stand
acceler rel current level japanes commerci
effort remain plan new geographi ad across
europ domest shock util also remain sound effort
re-acceler high-risk pci growth long-term place
recent domest sale expans reorgan expect
complet fye howev expect re-acceler high-
risk pci sale growth requir time result continu
forecast mid-teen annual revenu growth prior
success re-acceler annual sale growth
aid favor new product cadenc increas train
educ data
share remain unchang recal price target impli
revenu multipl approxim
revis estim follow report fiscal
oper result revis revenu
earn estim reflect compani fy actual result
guidanc updat specif reduc former
million revenu estim million million
revis earn estim per share regard
later note prior publish estim reflect non-
recur gain exclud impli per
share estim revis former billion
revenu earn estim billion per
previous establish oper guidanc assign
emphasi lower bound annual revenu guidanc specif
compani expect annual report revenu growth
million million pre-cal consensu
million emphasi lower bound guidanc
oper margin rang pre-cal consensu
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
fiscal summari review fiscal total revenu increas annual million pre-cal
consensu million/stephen estimate million impella product revenu increas
million util increas annual intern sale increas million european
sale increas japanes adopt continu acceler yield quarterli revenu million
quarterli gross margin declin year year result smartassist launch mix
off-set plant product total oper expens increas year year research
develop expens increas sell gener administr expens increas yield
million oper incom result report oper margin quarter earn
per share includ charg unreal loss invest shockwav medic
rate excess tax benefit relat stock compens exclud state one-
time item report adjust earn per share oper period pre-cal consensu
fiscal period impella util slightli favor emerg indic versu
protect pci quarter furthermor open new site compar last year
result domest hospit impella cp impella penetr
impella penetr impella rp penetr lastli fiscal
oper period domest reorder rate slightli exceed averag combin inventori held
hospit impella cp unit consist fiscal level
balanc sheet review fiscal oper period gener million oper cash flow
repres annual increas result exit fiscal oper period million
cash market secur debt yield net cash per share opinion favor
oper model character high cash flow gener combin cash rich balanc sheet untap
credit capac provid suffici financi latitud fund work capit need invest
oper initi pursu strateg opportun may aris via fund oper
valuat summari share current valu revenu versu compar peer trade
like multipl admittedli share still possess notabl rel premium view merit
base compani larg exist effect monopoli busi model top tier gross
oper margin profil profit debt free cash rich balanc sheet
consolid statement incom
dollar thousand except per share data
product revenu
research develop
sell gener administr
total incom expens
fiscal period
fiscal period
incom continu oper tax
tax incom continu oper
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
